Alkermes’s Promising Orexin Drug Development Positions Company for Market Leadership
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...
Philippine Daily Inquirer7h
How to help someone with schizophrenia in the Philippines
The World Health Organization celebrates World Mental Health Day today,. In response, Filipinos should learn how to handle ...
Why don’t your psychiatric drugs work better?
In 2023 alone, the US National Institutes of Health (NIH) poured $1.25 billion into research studying how mental illness ...
The Pharma Letter16h
Schizophrenia win for BMS’ Cobenfy, but challenges lie ahead, says analyst
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline ...
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight
The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...
DEA could reclassify marijuana to a less restrictive category – a drug policy expert weighs the pros and cons
Moving marijuana to a less restrictive category under the Controlled Substances Act poses benefits and potential risks. But ...
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.